Vertex welcomes extended approval for cystic fibrosis therapy

Vertex has welcomed the TGA’s approval of a new indication for ORKAMBI (lumacaftor and ivacaftor) to include children aged one to less than two years who have two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene. …